A VIRTUAL REALITY IN PRACTICE VIEW: Maximizing Clinical Benefit Through Optimal LDL-C Reductions in Patients With Acute Coronary Syndrome
Harold E. Bays MD, FOMA, FTOS, FACC, FACE, FNLA
Louisville Metabolic and Atherosclerosis
Research Center Inc.
Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Professor, Harvard Medical School
Brigham and Women’s Hospital
Division of Cardiovascular Medicine
This case-based enduring activity will cover the diagnosis, treatment and management of patients with cardiovascular disease (CVD).
This activity is intended for interventional cardiologists involved in the management of patients at high risk for CVD due to hypercholesterolemia.
Upon completion of the program, attendees should be able to:
- Describe the atherosclerotic pathology secondary to chronic hypercholesterolemia;
- Review the contrasting pharmacodynamics of LDL-C-lowering agents in patients with atherosclerotic disease;
- Examine the efficacy and safety of PCSK9 antibody therapy through the review of clinical trial data in the management of high-risk patients; and
- Discuss the medical economics of PCSK9 inhibition in the patient post-ACS on maximally-tolerated statin therapy.
ACCREDITATION AND DESIGNATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with CVD. Credits: 1.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Neither Dr. Harold Bays, nor his affiliated research center & weight management center, own pharmaceutical stocks or patents. In the past 12 months, Dr. Harold Bays' research site has received research grants from Acasti, Alere, Allergan, Amarin, Amgen, Arena, Astrazeneca, Boehringer Ingelheim, Bristol Meyers Squibb, ChromaDex, Dr. Reddy, Eisai, Esperion, Ferrer/Chiltem, Gan and Lee, Gemphire, Gilead, GSK, Home Access, ispecimen, Ionis, Janssen, Johnson and Johnson, LIB Therapeutics, Medlmmune, Merck, Necktar, Nichi-Iko, Novartis, NovoNordisk, Omthera, Pfizer, Regeneron, Sanofi, Selecta, Takeda, and TIMI.
In the past 12 months, Dr. Harold Bays has served as a consultant/advisor for Aegerion, Amarin, Amgen, Astrazeneca, Boehringer Ingelheim, ChromaDex, Esperion, Gemphire, Janssen, Johnson & Johnson, Kowa, Merck, Novartis, Prosciento, Regeneron, and Sanofi.
In the past 12 months, Dr. Harold Bays has served as a speaker for Amarin, Amgen, Kowa, Regeneron, and Sanofi.
Dr. Deepak Bhatt has received research funding from Abbott, Amrin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Rose, Sanofi Aventis, Synaptic, and The Medicines Company.
The independent reviewers, staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Manager for Med Learning Group has nothing to disclose.
Chris Drury, MA, MA, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lisa Dorin, Senior Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: September 27, 2018
EXPIRATION DATE: September 27, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.